SCHEMBL5000478

SCHEMBL5000478

COC(=O)COc1ccccc1Cl

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
HPGD P15428 2/20 0.61
TSHR P16473 1/20 0.61
RAB9A P51151 2/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
POLB P06746 3/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MAPT P10636 3/20 0.56
KDM4E B2RXH2 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
PKM P14618 1/20 0.54
SENP2 Q9HC62 1/20 0.54
SENP1 Q9P0U3 1/20 0.54
HTT P42858 1/20 0.54
RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10506317 0.87 SMN1; SMN2 (0.60) LMNAHPGDTSHRMEN1KMT2A
SCHEMBL8816518 0.86 LMNA (0.58) LMNAHPGDTSHRMEN1KMT2A
SCHEMBL11196941 0.83 KMT2A (0.59) LMNAHPGDTSHRRAB9AMEN1
SCHEMBL2011265 0.83 USP2 (0.58) LMNAHPGDTSHRRAB9AMEN1
SCHEMBL15391794 0.81 SMN1; SMN2 (0.70) LMNAHPGDRAB9AKMT2APOLB
SCHEMBL5523413 0.81 KMT2A (0.57) LMNAHPGDTSHRRAB9AMEN1
SCHEMBL13941921 0.81 L3MBTL1 (0.51) LMNAHPGDTSHRRAB9AMEN1
SCHEMBL8426765 0.81 HPGD (0.64) LMNAHPGDTSHRRAB9AMEN1
SCHEMBL5000233 0.80 LMNA (0.55) LMNATSHRRAB9AMEN1KMT2A
SCHEMBL6243487 0.80 GAA (0.57) LMNAHPGDTSHRRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104513186-B A kind of preparation method of optically pure dextrorotation Cloprostenol Sodium 宁波第二激素厂 2016-10-05 CN claimed
CN-104513186-A Preparation method of optically pure dextro cloprostenol sodium Ningbo second hormone factory 2015-04-15 CN claimed
WO-2024128359-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES 전남대학교산학협력단 2024-06-20 WO disclosed
WO-2024128359-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES 전남대학교산학협력단 2024-06-20 WO disclosed
CN-108947816-A A kind of preparation method of chloro phenoxy acetic acid ester 山东润博生物科技有限公司 2018-12-07 CN disclosed
CN-104513186-B A kind of preparation method of optically pure dextrorotation Cloprostenol Sodium 宁波第二激素厂 2016-10-05 CN disclosed
CN-104513186-A Preparation method of optically pure dextro cloprostenol sodium Ningbo second hormone factory 2015-04-15 CN disclosed
CN-103282346-B Process for preparation of phenyl carbamate derivatives BIO PHARM SOLUTIONS CO LTD 2014-11-19 CN disclosed
CN-101432278-B Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL MYERS SQUIBB CO 2012-11-28 CN disclosed
CN-101432278-A Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL MYERS SQUIBB CO (US) 2009-05-13 CN disclosed
US-7449581-B2 6-Substituted pyrido-pyrimidines POCHE PALO ALTO LLC (US) 2008-11-11 US disclosed
EP-1611105-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2006-01-04 EP disclosed
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 CN disclosed
EP-1361880-B1 6-SUBSTITUTED PYRIDO-PYRIMIDINES HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
WO-2004094386-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed
US-20040116698-A1 6-Substituted pyrido-pyrimidines CHEN JIAN JEFFREY (US) 2004-06-17 US disclosed
US-6696566-B2 SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES SYNTEX (U.S.A.) LLC 2004-02-24 US disclosed
EP-1361880-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-19 EP disclosed
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. SYNTEX (U.S.A.) LLC 2003-09-11 US disclosed
WO-2002064594-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. ARRB1, MAPK1, MAPK8 LMNA 4583/4885HPGD 623/4885TSHR 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.